IntroductionSchnitzler syndrome (SchS) is a rare, late-onset, acquired autoinflammatory disorder characterized by recurrent urticarial lesions, monoclonal gammopathy and systemic inflammation. Although interleukin-1 (IL-1) blockade with anakinra is con…
In enzootic bovine leukosis (EBL), a B-cell lymphoma caused by bovine leukemia virus (BLV) infection, immune remodeling within tumor-affected lymph nodes is currently poorly understood. Here, we analyzed chemokine production and macrophage phenotypes i…
BackgroundThe prevalence of female sexual dysfunction (FSD) among women with systemic lupus erythematosus (SLE) is inconsistent, and whether SLE is a risk factor for FSD among women remains controversial. Therefore, this study aimed to conduct a system…
BackgroundSeptic cardiomyopathy (SCM) is one of the most common and serious complications of sepsis. Earlier research has identified reciprocal regulation between SCM and gut microbiota (GM), but the mechanistic basis of GM in SCM development remains o…
BackgroundNeutrophils, which are polymorphonuclear leukocytes of the phagocytic system, serve as critical mediators of inflammation-induced injury and are implicated in various diseases. However, the role of neutrophils in primary Sjögren’s syndrome (p…
BackgroundSleep disruption(SD) has been shown to amplify inflammatory signaling and promote pain hypersensitivity, but how inflammation interacts with brain functional alterations to drive pain sensitization remains unclear. This study therefore aims t…
IntroductionSystemic juvenile idiopathic arthritis-associated lung disease (sJIA-LD) is a rare, potentially fatal complication of sJIA, often accompanied by pulmonary hypertension (PHTN) and macrophage activation syndrome (MAS). The underlying pathophy…
Malignant lung tumors are the leading cause of cancer-related mortality worldwide, and therefore remodeling of the tumor microenvironment (TME) has become an important strategy to overcome anti-tumor therapy resistance in lung cancer. Flavonoid compone…
Targeted B-cell depletion via the anti-CD20 monoclonal antibody rituximab fundamentally altered the therapeutic algorithm for rheumatoid arthritis (RA). Despite its clinical entrenchment, approximately 40% of patients exhibit primary or secondary non-r…
